Multiple sclerosis | Neurology Clinical Practice
Alemtuzumab scFv fragments and CD52 interaction study through molecular dynamics simulation and binding free energy - ScienceDirect
1 Campath ® (alemtuzumab) Millennium & ILEX Partners, LP Oncologic Drugs Advisory Committee December 14, ppt download
Frontiers | Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant | Immunology
Biomedicines | Free Full-Text | Monoclonal Antibodies in Multiple Sclerosis: Present and Future | HTML
Alemtuzumab in Multiple Sclerosis
The safety and side effects of monoclonal antibodies | Nature Reviews Drug Discovery
Intractable and highly active relapsing multiple sclerosis – rol | NDT
Identification and development of new therapeutics for multiple sclerosis: Trends in Pharmacological Sciences
Cells | Free Full-Text | The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis | HTML
JPM | Free Full-Text | Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis | HTML
NUOVI FARMACI E TERAPIA PERSONALIZZATA NELLA SCLEROSI MULTIPLA - ppt download
Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. - Abstract - Europe PMC
A changing treatment landscape for multiple sclerosis: challenges and opportunities - Piehl - 2014 - Journal of Internal Medicine - Wiley Online Library
![PDF] Alemtuzumab and multiple sclerosis: therapeutic application. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1e654d2888bed763823fb85556c2696192e18cc3/4-Figure1-1.png "PDF] Alemtuzumab and multiple sclerosis: therapeutic application. | Semantic Scholar")
PDF] Alemtuzumab and multiple sclerosis: therapeutic application. | Semantic Scholar
![PDF] Multiple Sclerosis Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d1e94d3b73aa7cf229385cc2e3f8298d21ab842d/2-Figure2-1.png "PDF] Multiple Sclerosis Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis | Semantic Scholar")
PDF] Multiple Sclerosis Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis | Semantic Scholar
Frontiers | New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions | Immunology
Alemtuzumab Development of a Monoclonal Antibody < 발간보고서<자료실-제약산업정보포털
Intractable and highly active relapsing multiple sclerosis – rol | NDT
Alemtuzumab - Classes of Monoclonal Antibodies: CD Antigens
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results | Blood Cancer Journal
SciELO - Brasil - New immunosuppressive agents in pediatric transplantation New immunosuppressive agents in pediatric transplantation
